Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy

G L Banna; R Di Quattro; L Malatino; G Fornarini; A Addeo; M Maruzzo; V Urzia; F Rundo; H Lipari; U De Giorgi; U Basso

doi:10.1007/s12094-020-02337-3

Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy

G L Banna, R Di Quattro, L Malatino, G Fornarini, A Addeo, M Maruzzo, V Urzia, F Rundo, H Lipari, U De Giorgi, U Basso

Research output: Contribution to journal › Article › peer-review

Abstract

PURPOSE: To identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs).

METHODS/PATIENTS: We explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.

RESULTS: NLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069, p = 0.0034, p = 0.0160, p = 0.0063; p < 0.001, p = 0.021, p = 0.014, p = 0.026; for NLR-3, NLR-5, UIPI-3, UIPI-5, respectively) and overall survival when NLR cut-off was ≥ 5 (p = 0.03 and p = 0.024, for NLR-5 and UIPI-5, respectively).

CONCLUSIONS: NLR-5 deserves prospective validation to identify mUC patients with poor prognosis following ICIs.

Original language	English
Pages (from-to)	2130-2135
Number of pages	6
Journal	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Volume	22
Issue number	11
DOIs	https://doi.org/10.1007/s12094-020-02337-3
Publication status	Published - Nov 2020

Access to Document

10.1007/s12094-020-02337-3

Fingerprint Dive into the research topics of 'Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy'. Together they form a unique fingerprint.

Cite this

Banna, G. L., Di Quattro, R., Malatino, L., Fornarini, G., Addeo, A., Maruzzo, M., Urzia, V., Rundo, F., Lipari, H., De Giorgi, U., & Basso, U. (2020). Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 22(11), 2130-2135. https://doi.org/10.1007/s12094-020-02337-3

Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. / Banna, G L; Di Quattro, R; Malatino, L; Fornarini, G; Addeo, A; Maruzzo, M; Urzia, V; Rundo, F; Lipari, H; De Giorgi, U ; Basso, U.

In: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, Vol. 22, No. 11, 11.2020, p. 2130-2135.

Research output: Contribution to journal › Article › peer-review

Banna, GL, Di Quattro, R, Malatino, L, Fornarini, G, Addeo, A, Maruzzo, M, Urzia, V, Rundo, F, Lipari, H, De Giorgi, U & Basso, U 2020, 'Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy', Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 22, no. 11, pp. 2130-2135. https://doi.org/10.1007/s12094-020-02337-3

Banna GL, Di Quattro R, Malatino L, Fornarini G, Addeo A, Maruzzo M et al. Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2020 Nov;22(11):2130-2135. https://doi.org/10.1007/s12094-020-02337-3

Banna, G L ; Di Quattro, R ; Malatino, L ; Fornarini, G ; Addeo, A ; Maruzzo, M ; Urzia, V ; Rundo, F ; Lipari, H ; De Giorgi, U ; Basso, U. / Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. In: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2020 ; Vol. 22, No. 11. pp. 2130-2135.

@article{b13a1157a57240faa8206de886175aa9,

title = "Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy",

abstract = "PURPOSE: To identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs).METHODS/PATIENTS: We explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.RESULTS: NLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069, p = 0.0034, p = 0.0160, p = 0.0063; p < 0.001, p = 0.021, p = 0.014, p = 0.026; for NLR-3, NLR-5, UIPI-3, UIPI-5, respectively) and overall survival when NLR cut-off was ≥ 5 (p = 0.03 and p = 0.024, for NLR-5 and UIPI-5, respectively).CONCLUSIONS: NLR-5 deserves prospective validation to identify mUC patients with poor prognosis following ICIs.",

author = "Banna, {G L} and {Di Quattro}, R and L Malatino and G Fornarini and A Addeo and M Maruzzo and V Urzia and F Rundo and H Lipari and {De Giorgi}, U and U Basso",

year = "2020",

month = nov,

doi = "10.1007/s12094-020-02337-3",

language = "English",

volume = "22",

pages = "2130--2135",

journal = "Clinical and Translational Oncology",

issn = "1699-048X",

publisher = "Springer-Verlag Italia",

number = "11",

}

TY - JOUR

T1 - Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy

AU - Banna, G L

AU - Di Quattro, R

AU - Malatino, L

AU - Fornarini, G

AU - Addeo, A

AU - Maruzzo, M

AU - Urzia, V

AU - Rundo, F

AU - Lipari, H

AU - De Giorgi, U

AU - Basso, U

PY - 2020/11

Y1 - 2020/11

N2 - PURPOSE: To identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs).METHODS/PATIENTS: We explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.RESULTS: NLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069, p = 0.0034, p = 0.0160, p = 0.0063; p < 0.001, p = 0.021, p = 0.014, p = 0.026; for NLR-3, NLR-5, UIPI-3, UIPI-5, respectively) and overall survival when NLR cut-off was ≥ 5 (p = 0.03 and p = 0.024, for NLR-5 and UIPI-5, respectively).CONCLUSIONS: NLR-5 deserves prospective validation to identify mUC patients with poor prognosis following ICIs.

AB - PURPOSE: To identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs).METHODS/PATIENTS: We explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.RESULTS: NLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069, p = 0.0034, p = 0.0160, p = 0.0063; p < 0.001, p = 0.021, p = 0.014, p = 0.026; for NLR-3, NLR-5, UIPI-3, UIPI-5, respectively) and overall survival when NLR cut-off was ≥ 5 (p = 0.03 and p = 0.024, for NLR-5 and UIPI-5, respectively).CONCLUSIONS: NLR-5 deserves prospective validation to identify mUC patients with poor prognosis following ICIs.

U2 - 10.1007/s12094-020-02337-3

DO - 10.1007/s12094-020-02337-3

M3 - Article

C2 - 32232716

VL - 22

SP - 2130

EP - 2135

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

SN - 1699-048X

IS - 11

ER -